Introduction
Prostate cancer (PCa) is a major cancer problem among men. 1 The availability of PSA as a serum prostate biomarker coupled with a growing and aging population has resulted in a dramatic increase in the incidence of PCa. 2 In contemporary patients, PSA is most highly correlated with overall prostate volume, highlighting the need for 'marker [s] for PCa that [are] truly proportional to the volume and grade of this ubiquitous cancer'. 3 Conventional imaging with transrectal ultrasound (TRUS), computed tomography (CT), high-resolution magnetic resonance imaging (HR-MRI), ProstaScint or prostate-specific membrane antigen (PSMA) imaging and bone scan have historically been modest at best in detecting and staging clinically localized PCa. 4, 5 To address the limitations of existing imaging techniques in the diagnosis and staging of PCa, numerous imaging innovations have been developed: ultrasound Doppler alone or combined with micro-bubble contrast agent, three-dimensional stereotactic US (3D-US), higher-resolution 3 T MRI, endo-rectal coils MRI, dynamic contrast enhanced MRI (DCE-MRI), diffusion weighted MRI (DW-MRI) and MR spectroscopy (MRS), and lymph node imaging using sentinel lymph node detection and superparamagnetic nanoparticle techniques. [4] [5] [6] [7] One imaging innovation that has proved useful for metabolic imaging of many cancers is positron emission tomography (PET) or combined positron emission tomographycomputed tomography (PET/CT) using 2-[ 18 F]fluoro-2-deoxyglucose ( 18 F-FDG). 8 However, this modality is less accurate for the diagnosis and staging of PCa. [9] [10] [11] [12] Given the limitations of conventional imaging modalities, a PET/CT imaging agent tailored to prostate cancer detection would be a clear advance in prostate cancer localization and staging. Radiolabeled amino acid tracers such as anti-1-amino-3- Tc-bombesin, or radiolabeled androgen tracers such as 18 F-16b-fluoro5a-dihydrotestosterone ( 18 F-FDHT), or radiolabeled choline and choline analog probes such as 11 C-acetate, 11 C-choline and [
18 F]fluoromethyl-dimethyl-2-hydroxyethyl-ammonium ( 18 F-FCH) have been recently developed for prostate cancer imaging. 6, [12] [13] [14] In this systematic review, we summarize the available preclinical and clinical studies on 18 F-FCH imaging, and we make recommendations for the potential role of 18 F-FCH as an imaging biomarker in the management of PCa.
Choline metabolism in prostate cancer
Choline, as a component of phospholipids making up the cell membrane, is an excellent biomarker to image proliferating cancer cells. 15, 16 Alterations in choline metabolism have been demonstrated to be a common metabolic change in many cancers and are thought to reflect increased demands from proliferating cancer cells, but also may reflect changes in alterations in choline uptake and retention due to alterations in choline transport and the activity of choline kinase. [17] [18] [19] When labeled with 11 C, both choline and acetate substrates can be used to image PCa with PET and PET/CT. 11 C-acetate and 11 C-choline PET have been reported to be more sensitive than 18 F-FDG PET in the detection of primary lesions, regional lymph node and bone metastases. 5, 12, [14] [15] [16] Despite its relatively good imaging properties, however, the 20 min half-life of 11 C severely limits its utility in the clinic as it must be prepared for each imaging study and cannot be transported off-site. The longer half-life of 18 F (110 min) relative to 11 C (20 min) means that 18 F-fluorinated choline analogs have significant advantages over 11 C-choline and 11 C-acetate, not requiring an on-site cyclotron for production and higher specific activities. The shorter positron range of 18 F also means better spatial resolution and better image quality.
Materials and methods
The synthesis of 18 F-FCH ( Figure 1 ) was first described by DeGrado in 2001. 20, 21 We thus limited our literature search from January 2001 to August 2011. A PubMed search using the terms ('positron emission tomography' OR 'PET') AND ('prostate cancer') AND ('choline'), or (' 18 F-fluorocholine') AND ('prostate cancer') was used to identify 37 relevant preclinical and clinical studies evaluating the use of 18 F-FCH for PCa imaging. In addition, bibliographies of retrieved papers were reviewed to identify other relevant studies. In many instances, single papers addressed multiple clinical scenarios. Thus, there is some overlap in the reference list that follows. Seven studies detailing the radiosynthesis of 18 F-FCH, preclinical and early clinical dosimetry and biodistribution in humans were identified. [20] [21] [22] [23] [24] [25] [26] Clinical studies included six articles for evaluation of local disease, 27 39, 48 Seven studies evaluated 18 F-FCH for defining intra-prostatic lesions or limited lymph node recurrence for dose-escalated radiotherapy. 47, [49] [50] [51] [52] [53] [54] Two clinical studies evaluated the physiological distribution and false-positive 18 F-FCH uptakes. 55, 56 The literature data on 18 F-FCH prostate cancer imaging are summarized in Table 1 . 20, 21 In humans, 18 F-FCH uptake was most pronounced in the kidneys and liver. Rapid clearance from the blood was noted with background clearance of the agent within 4-5 min of injection. The liver and lung uptake plateau was reached at 10 min post-intravenous injection. [20] [21] [22] [23] Imaging of metastases in PCa patients was markedly better with 18 F-FCH compared with 18 F-FDG, and a reduction in 18 F-FCH uptake was noted with the institution of androgen deprivation therapy. 20, 21 In both androgen-dependent and androgenindependent PCa patients, 18 F-FCH PET detected more primary tumors, bone and lymph node metastases than 18 F-FDG PET and the 18 F-FCH maximum standard uptake value (SUVmax) was significantly higher than the 18 F-FDG SUVmax. 24 More recently, fully-automated methods for the radiosynthesis of F-FDG cyclotron synthesizer modules have been described, increasing the clinical feasibility of imaging with this agent. 25, 26 FCH PET or PET/CT acquisition protocol has been established for PCa imaging, although most authors recognize the need to incorporate a component of early imaging to avoid interference from bladder accumulation. Dynamic acquisition over the pelvis followed by a whole-body PET or PET/CT static acquisition including the pelvis has been proposed as allowing visualization of pelvic disease without interference from bladder uptake (dynamic imaging) while allowing maximum sensitivity for distant disease (delayed whole-body PET or PET/CT). 20, 21, 24, 34, 35, 37, 38, 42, 57 Early time points for imaging (0-15 min post-intravenous injection) and/or delayed imaging time points (30, 40, 45, 60 , 90-120 and 65-200 min post-intravenous injection) have been also described in the published literature. 22 
Clinical applications
In PCa patients, 18 F-FCH imaging has been investigated for initial staging, re-staging (for example, recurrent disease and castrate-resistant disease), treatment monitoring and treatment planning. Informed and written consent was given by all patients, which were most often enrolled into clinical trials with ethics committee approval. In the 37 relevant articles published from 2001-2011 (Table 3) or Gleason score 46) who had a sentinel lymph node detection and extended pelvic lymph node dissection at the time of radical prostatectomy, with confirmation of nodal metastases in 10/20 men studied. Overall, 18 F-FCH PET/CT only had 10% sensitivity and 80% specificity for the detection of lymph node metastases in this population. Specifically, 18 F-FCH PET/CT had nine falsenegative results related to lymph node metastases with a maximal diameter of 0.2-8 mm, whereas these patients were identified with sentinel lymph node detection. In one patient with a massively invaded lymph node, 18 F-FCH PET/CT was positive, while sentinel lymph node detection was falsely negative. 35 F-FCH scans in 54 patients examined for rising PSA post-radical prostatectomy (n ¼ 58), radical radiotherapy (n ¼ 21) or while on hormones (n ¼ 21). They noted that the 18 F-FCH scans were rarely (3/38) positive among patients with PSA o4 ng ml À1 and initial Gleason grade p7, whereas all patients with a PSA 44 ng ml À1 and Gleason score 47 had positive scans. In patients with PSA o4 ng ml
À1
and Gleason score 47,
18
F-FCH PET/CT was positive in 54% of patients. 41 Likewise, Pelosi et al. 43 noted an overall detection rate of 42.9% in 24/56 patients with rising PSA post-prostatectomy, and noted an increase in positive 18 F-FCH scans with higher PSA at recurrence (20% at PSA o1ng ml
À1
; 44% at PSA ¼ 1-5 ng ml
; 82% 18 F-fluorocholine for prostate cancer imaging G Bauman et al at PSA 45 ng ml À1 ). 43 In a series of 111 PCa patients including 68 patients with biochemical recurrence, 18 F-FCH imaging was able to detect local, nodal and bone recurrences. Importantly, 18 F-FCH PET/CT was found reliable for detection of PSA recurrence 42 ng ml À1 with a good sensitivity of 83-87%, whereas 18 F-FCH imaging had a moderate sensitivity of 70-75% for a PSA recurrence o2 ng ml
, and for small lymph node metastases (o1 cm) with minimal 18 F-FCH uptake. 36 In a series of 71 PCa with a PSA recurrence after previous surgery and/or radiation therapy, Casamassima et al. 47 highlighted the usefulness of 18 40 Although the overall sensitivity for detecting any recurrence with 18 F-FCH imaging at PSA levels X2-5 ng ml À1 seems to be acceptable (X80%), the sensitivity for detection of prostate bed and small lymph node recurrences at PSA levels o2-5 ng ml À1 is lower (E50%). 34, [41] [42] [43] [44] [45] This may reflect the fact that isolated local recurrence is more likely at lower PSA levels and these recurrences may be more difficult to detect owing to challenges in distinguishing between prostate bed uptake and bladder accumulation of tracer, particularly for small volume recurrences. 34 F-FCH true-positive and true-negative lesions after a follow-up of 2 years. False-positive results were related to inflammatory lymph nodes detected o5 min with decreased uptake 420 min post-intravenous injection. 
False-negative results were related to sclerotic metastases and iliac metastases post-radiation therapy.
18
F-FCH imaging had sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive values of 96%, 96%, 96%, 99% and 81%, respectively, for the detection of bone and soft-tissue metastases in castrateresistant patients. 48 Table 6 summarizes the literature data on 18 F-FCH PET and PET/CT in castrate-resistant prostate cancer.
Evaluation of treatment response. Conventional imaging modalities such as bone scan and CT scan are used to monitor the effect of androgen ablation therapy. However, imaging changes may lag behind tumor response. 18 F-FDG PET was also examined for its usefulness in assessing treatment response in prostate cancer. Although early preclinical studies were disappointing, later studies showed that the early changes in glucose metabolism could enable monitoring metabolic changes in prostate tumors after treatment, particularly in advanced disease with aggressive PCa. 14 Beheshti et al. 37, 38 showed that reduced 18 F-FCH uptake is seen often without any significant morphological CT changes when comparing pre-and post-therapeutic studies in prostate cancer patients who respond to the hormone therapy (see Figure 3) ; thus, demonstrating the potential of 18 F-FCH imaging for early metabolic response assessment of hormone therapy. Casamassima et al. 47 also showed that PET/CT allows radiation therapy monitoring with or without hormone therapy in recurrent PCa patients with limited nodal disease at 60 days after stereotactic body radiation therapy, thereby, saving or postponing systemic androgen therapy; 13 patients had complete remission, while 8 patients had recurrences in non-irradiated and prophylactically irradiated areas. In 30 hormone refractory PCa patients, Kwee et al. 39 showed that 18 F-FCH imaging was able to perform RECIST (for example, response evaluation criteria in solid tumors) measurements in up to half of patients (47%) with non-prostatic tissue lesions. In skeletal lesions, 18 F-FCH imaging might provide a more objective bone end point for clinical trials compared with conventional bone scintigraphy.
39 Table 7 summarizes the literature data on 18 F-FCH PET and PET/CT in the treatment response monitoring of PCa.
Radiotherapy planning. Radiotherapy dose escalation to the whole prostate has been shown to be associated with improved disease control, but at the cost of higher gastrointestinal and genitourinary toxicity. 59 Histopathology studies demonstrating that most PCa men 60,61 Such a strategy requires accurate localization of DILs through combinations of biopsy information and imaging. 62 Pinkawa et al. 49 described the use of 18 F-FCH PET/CT for delineation of DILs in radiation treatment planning for 66 PCa patients. DILs were identified in all patients, typically in the periphery of the prostate within 5-10 mm of the bladder and rectal wall. An earlier study of a smaller number of PCa patients (n ¼ 12) using the same 18 F-FCH PET/CT SUVmax criteria to define DILs modeled the ability to escalate dose to the DILs to 80-83 Gy with a whole prostate dose of 76 Gy, whereas maintaining dose to the bladder and rectum within acceptable limits. 50 In comparison, Niayazi et al. 53 modeled the potential benefit of 18 F-FCH defined lesions. The benefit of a DIL boosting strategy was modest at best, and was dependent on the assumed sensitivity of the 18 F-FCH PET study. Wang et al. 51 examined 17 patients with suspected intra-prostatic post-radiation failures with 18 F-FCH scans; 19 lesions were detected with mean volumes of 5-10 cm 3 depending on the segmentation technique used (manual vs automated based on SUV). In 10 patients with biopsy confirmation of recurrence, positive cores were found on the same side as the 18 F-FCH defined lesion. The authors concluded that 18 F-FCH PET/CT may be useful for defining recurrences within the prostate for focal salvage therapy. 51 Modeling studies on the use of 18 F-FCH for the definition of volumes after adaptative segmentation techniques for focal radiotherapy boost in either primary disease or recurrent disease have also been described. [52] [53] [54] In a series of 71 PCa patients with biochemical failure after external radiation therapy with or without hormone therapy, 18 F-FCH PET/CT was used for stereotactic body radiation therapy of limited nodal recurrence (pelvic and/or para-aortic and/or mediastinal lymph node recurrences). In pre-treatment RT planning, PET combined to a cone beam CT allowed precise delineation of GTV, delivery of three hypofractionated high doses (30 Gy to lymph node recurrence Table 7 18 F-FCH PET and PET/CT in the evaluation of treatment response in prostate cancer: literature data Literature data ref.
Number of patients Treatment Imaging technique
Keypoints of the literature data
Beheshti et al. 37 
21
HT PET/CT 1. In PCa patients under HT, CT sclerotic metastases may be seen without 18 F-FCH uptake; this may be related to the healing process in non-viable lesions. Beheshti et al. 38 
38
HT PET/CT Casamassima et al. 47 
71
SBRT ± HT PET/CT 2. In PCa patients with limited nodal recurrence, 18 F-FCH PET/CT may allow treatment monitoring at 60 days after SBRT ± HT. Kwee et al. sites, and 50 þ 24 Gy boost volume to the whole pelvis) and reduction of gastrointestinal toxicity. In patients treated with stereotactic body radiation therapy, 3-year overall survival was 92%, and 3-year disease control was 90%. 47 Table 8 summarizes the literature data on 18 F-FCH PET and PET/CT in radiation therapy planning.
Limitations of the literature data
Although more than 1200 PCa patients have been assessed with 18 F-FCH PET and PET/CT in 37 relevant preclinical and clinical studies (see Table 3 ), the number of subjects enrolled in unicenter studies varied from 1 patient (for example, dosimetry and biodistribution studies) to 130 (for example, preoperative staging) contributing to variability in reported outcomes related to case series size. 21, 30 Variability in the reported performance of 18 F-FCH PET and PET/CT also reflects the heterogeneity among the reported clinical studies: mixture of primary tumors, recurrent and metastatic disease and variability in Gleason scores and PSA levels at the time of scanning. Scanning protocols differed significantly among studies, particularly in the timing of scan acquisition and the use of PET vs PET co-registered with diagnostic CT vs hybrid PET/CT acquisition. In addition to variations in scanning techniques, each study validated the 18 F-FCH scans by a variety of means: correlation with clinical outcomes, consensus gold standards based on clinical and standard imaging, or histopathological results. Particularly, the lack of biopsy confirmation within many of the patients studied needs to be considered; for example, Schillaci et al. 56 noted a relatively high frequency (E19%) of false-positive results related to benign inflammatory lesions or other neoplasms.
Summary and recommendations
Although the feasibility of 18 F-FCH imaging for the staging of primary and recurrent PCa, the planning of prostate biopsy and radiation therapy, and the treatment monitoring has been demonstrated, the overall performance of this modality remains unclear. On the basis of the evidence to date, the use of 18 F-FCH imaging might be considered in clinical trials. Evaluation of 18 F-FCH imaging in prospective multicenter studies with larger populations of well-defined PCa patients with standardized scanning protocols and well-defined gold standard is necessary to better define the utility of 18 F-FCH imaging. In designing such studies, a standardized scanning protocol is recommended, and the literature data would suggest the use of 4 MBq kg À1 18 F-FCH with dynamic PET/CT imaging during the interval time from 0 to 15 min post-intravenous injection, followed by whole-body PET/CT as a reasonable protocol to maximize the performance of the 18 F-FCH imaging while minimizing potential interference due to urinary excretion of the tracer. Potential areas for evaluation of 18 F-FCH in clinical trials are summarized in Table 9 .
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